Subgroup analysis in clinical trials constitutes a vital methodological tool to uncover differential treatment effects within specified categories of patients. This approach enables researchers to ...

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal study of patients with extra-pancreatic neuroendocrine ...

Primary and subgroup analysis from the Phase 2b CORAL trial of nalbuphine ER for the treatment of patients with IPF-related chronic cough ...

Meaningful efficacy observed in slow-progressor subgroup; NfL biomarker improvements support potential for accelerated regulatory pathway SEOUL, South Korea, May 29, 2025 /PRNewswire/ -- Neuronata-R®, ...

ALAMEDA, Calif.--(BUSINESS WIRE)-- Exelixis, Inc. (EXEL) (Nasdaq: EXEL) today announced results from a subgroup analysis of the CABINET phase 3 pivotal trial evaluating CABOMETYX ® (cabozantinib) ...

MONTPELLIER, France--(BUSINESS WIRE)--Analysis of a major subgroup of patients undergoing a first Total Knee Replacement (TKR), representing over 70% of the trial population (108 out of 151), revealed ...

Add Yahoo as a preferred source to see more of our stories on Google. In NCFB On 30 September 2025, at the European Respiratory Society (ERS) Conference, held in Amsterdam, the Netherlands, Insmed ...

In oncology drug development, biomarker-driven studies are pivotal, enabling the selection of patient populations most likely to benefit from specific therapeutic interventions. These studies have ...

Rozanolixizumab effectively treats MuSK autoantibody-positive generalized myasthenia gravis, showing significant improvement in MG-ADL scores compared to placebo. MuSKgMG is more severe and ...

We review Bayesian and Bayesian decision theoretic approaches to subgroup analysis and applications to subgroup-based adaptive clinical trial designs. Subgroup analysis refers to inference about ...

SENIOR-RITA subgroup data showed primary composite events in 37.7% with invasive therapy versus 29.4% with conservative care ...